shutterstock_1857404794_michael_vi
Michael Vi / Shutterstock.com
25 February 2021Big PharmaAlex Baldwin

BGI secures appeal trial over Illumina DNA verdict

Chinese genome sequencing company BGI has been given the go-ahead to appeal an English High Court ruling in an ongoing lawsuit launched by competitor Illumina regarding its DNA sequencing patents.

The court had earlier ruled against BGI’s subsidiary MGI on 21 January this year, confirming that it had infringed on four out of five of Illumina’s valid sequencing patents.

The five patents are EP 1,530,578, EP 3,002,289, EP 3,587,433, EP 1,828,412 and EP 2,021,415.

An MGI spokesperson said in a statement: “We welcome the court’s decision to give us the permission to appeal the judgment, and we intend to file its appeal with the Court of Appeal. As permitted by the court, we will continue to supply sequencing reagents to our existing customers in the UK during the appeal period.

“We strongly oppose the abuse of patent litigation to maintain market monopoly and suppress fair competition.”

During the proceedings, the court ruled that the ‘412 patent was invalid due to obviousness and MGI is seeking to appeal the infringement verdict on the ‘415 patent.

“We concur with the court's previous ruling that Illumina’s ‘412 to methods of sequencing by synthesis using ascorbic acid is invalid for obviousness and that BGI’s CoolMPS sequencing method does not infringe this patent, as well as the finding that MGI’s CoolMPS sequencing does not infringe the ‘415 patent.”

MGI alleges that all five of Illumina’s patents are not valid, nor are they infringed by MGI’s CoolMPS and StandMPS sequencing systems.

“We are disappointed with the rulings on other mentioned patents. We continue to firmly believe that these patents are invalid and/or not infringed by MGI’s proprietary CoolMPS and StandMPS technologies,” said MGI’s spokesperson.

The two companies are currently locked in several lawsuits surrounding patent infringements in the UK, Hong Kong, and the US.

After the January ruling, Illumina’s senior vice-president and general counsel, Charles Dadswell, said the company will “continue to vigorously protect” its IP from BGI’s “willful” infringement.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox


More on this story

Big Pharma
27 May 2021   Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.
Medtech
2 September 2021   The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial.
Asia
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.

More on this story

Big Pharma
27 May 2021   Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.
Medtech
2 September 2021   The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial.
Asia
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.